



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10760A				SERIAL NO. 09/883,752								
		APPLICANT J. C. KATH												
		FILING DATE JUNE 18, 2001				GROUP 1614								
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
MB		6	2	2	5	3	1	8	5/2001	Sobolov-Jaynes				
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
MB		9	6	1	5	1	1	8	5/96	WIPO				
MB		9	7	3	0	0	3	4	8/97	WIPO				
MB		9	9	3	5	1	3	2	7/99	WIPO				
MB		9	9	3	5	1	4	6	7/99	WIPO				
MB		0	0	2	1	9	5	5	4/00	WIPO				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
MB		Vincent, et al.; Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts; Cancer Chemother Pharmacol; 45:231-238 (2000).												
MB		Showalter, et al.; Tyrosine Kinase Inhibitors; J. Med. Chem.; 42:5464-5474 (1999).												
MB		Hennequin, et al.; Design and Structure - Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors; J. Med. Chem.; 42:5369-5389 (1999).												
MB		Wedge, et al.; ZD4190: An Orally Active Inhibitor of Vascular Endothelial Growth Factor Signaling with Broad-Spectrum Antitumor Efficacy; Cancer Research; 60:970-975 (2000).												
EXAMINER		DATE CONSIDERED												
MB		12/30/02												
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														